BioCryst announces results From OPuS-2
BioCryst announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for prophylactic treatment of hereditary angioedema attacks. February 08, 2016